These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 17329551)

  • 1. Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vivo studies.
    Rizzi A; Gavioli EC; Marzola G; Spagnolo B; Zucchini S; Ciccocioppo R; Trapella C; Regoli D; Calò G
    J Pharmacol Exp Ther; 2007 Jun; 321(3):968-74. PubMed ID: 17329551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vitro studies.
    Spagnolo B; Carrà G; Fantin M; Fischetti C; Hebbes C; McDonald J; Barnes TA; Rizzi A; Trapella C; Fanton G; Morari M; Lambert DG; Regoli D; Calò G
    J Pharmacol Exp Ther; 2007 Jun; 321(3):961-7. PubMed ID: 17329552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence.
    Witkin JM; Statnick MA; Rorick-Kehn LM; Pintar JE; Ansonoff M; Chen Y; Tucker RC; Ciccocioppo R
    Pharmacol Ther; 2014 Mar; 141(3):283-99. PubMed ID: 24189487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative study of the antagonistic effect of (-)-cis-1-Methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol (SB-612111) on nociceptin/orphanin FQ-mediated potassium channel activation in rat periaqueductal gray slices.
    Liao YY; Jiang F; Chiou LC
    Eur J Pharmacol; 2011 Apr; 657(1-3):84-8. PubMed ID: 21300055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease.
    Arcuri L; Viaro R; Bido S; Longo F; Calcagno M; Fernagut PO; Zaveri NT; Calò G; Bezard E; Morari M
    Neurobiol Dis; 2016 May; 89():55-64. PubMed ID: 26804029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/mu-opioid receptor agonists.
    Khroyan TV; Polgar WE; Jiang F; Zaveri NT; Toll L
    J Pharmacol Exp Ther; 2009 Dec; 331(3):946-53. PubMed ID: 19713488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effects of nociceptin/orphanin FQ (NOP) receptor agonists in acute versus chronic pain: studies with bifunctional NOP/μ receptor agonists in the sciatic nerve ligation chronic pain model in mice.
    Khroyan TV; Polgar WE; Orduna J; Montenegro J; Jiang F; Zaveri NT; Toll L
    J Pharmacol Exp Ther; 2011 Nov; 339(2):687-93. PubMed ID: 21859931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo pharmacological characterization of the nociceptin/orphanin FQ receptor ligand Ac-RYYRIK-ol.
    Gündüz O; Rizzi A; Baldisserotto A; Guerrini R; Spagnolo B; Gavioli EC; Kocsis L; Magyar A; Benyhe S; Borsodi A; Calò G
    Eur J Pharmacol; 2006 Jun; 539(1-2):39-48. PubMed ID: 16682024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antidepressant-like effects of the nociceptin/orphanin FQ receptor antagonist UFP-101: new evidence from rats and mice.
    Gavioli EC; Vaughan CW; Marzola G; Guerrini R; Mitchell VA; Zucchini S; De Lima TC; Rae GA; Salvadori S; Regoli D; Calo' G
    Naunyn Schmiedebergs Arch Pharmacol; 2004 Jun; 369(6):547-53. PubMed ID: 15197534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of nociceptin/orphanin FQ-NOP receptor signalling produces antidepressant-like effects: pharmacological and genetic evidences from the mouse forced swimming test.
    Gavioli EC; Marzola G; Guerrini R; Bertorelli R; Zucchini S; De Lima TC; Rae GA; Salvadori S; Regoli D; Calo G
    Eur J Neurosci; 2003 May; 17(9):1987-90. PubMed ID: 12752799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modification of nociception and morphine tolerance by the selective opiate receptor-like orphan receptor antagonist (-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol (SB-612111).
    Zaratin PF; Petrone G; Sbacchi M; Garnier M; Fossati C; Petrillo P; Ronzoni S; Giardina GA; Scheideler MA
    J Pharmacol Exp Ther; 2004 Feb; 308(2):454-61. PubMed ID: 14593080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beta-arrestin 2 rather than G protein efficacy determines the anxiolytic-versus antidepressant-like effects of nociceptin/orphanin FQ receptor ligands.
    Asth L; Ruzza C; Malfacini D; Medeiros I; Guerrini R; Zaveri NT; Gavioli EC; Calo' G
    Neuropharmacology; 2016 Jun; 105():434-442. PubMed ID: 26867504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endogenous nociceptin/orphanin FQ signalling produces opposite spinal antinociceptive and supraspinal pronociceptive effects in the mouse formalin test: pharmacological and genetic evidences.
    Rizzi A; Nazzaro C; Marzola GG; Zucchini S; Trapella C; Guerrini R; Zeilhofer HU; Regoli D; Calo' G
    Pain; 2006 Sep; 124(1-2):100-8. PubMed ID: 16697109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spinal antinociceptive effects of the novel NOP receptor agonist PWT2-nociceptin/orphanin FQ in mice and monkeys.
    Rizzi A; Sukhtankar DD; Ding H; Hayashida K; Ruzza C; Guerrini R; Calò G; Ko MC
    Br J Pharmacol; 2015 Jul; 172(14):3661-70. PubMed ID: 25828800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo studies on UFP-112, a novel potent and long lasting agonist selective for the nociceptin/orphanin FQ receptor.
    Rizzi A; Spagnolo B; Wainford RD; Fischetti C; Guerrini R; Marzola G; Baldisserotto A; Salvadori S; Regoli D; Kapusta DR; Calo G
    Peptides; 2007 Jun; 28(6):1240-51. PubMed ID: 17532097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute and chronic antiparkinsonian effects of the novel nociceptin/orphanin FQ receptor antagonist NiK-21273 in comparison with SB-612111.
    Marti M; Mela F; Budri M; Volta M; Malfacini D; Molinari S; Zaveri NT; Ronzoni S; Petrillo P; Calò G; Morari M
    Br J Pharmacol; 2013 Feb; 168(4):863-79. PubMed ID: 22994368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel potent agonist [(pF)Phe4,Aib7,Aib11,Arg14,Lys15]N/OFQ-NH2 and antagonist [Nphe1,(pF)Phe4,Aib7,Aib11,Arg14,Lys15]N/OFQ-NH2 of nociceptin/orphanin FQ receptor.
    Peng YL; Chang M; Dong SL; Li W; Han RW; Fu GX; Chen Q; Wang R
    Regul Pept; 2006 May; 134(2-3):75-81. PubMed ID: 16516988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NOP Receptor Antagonists Decrease Alcohol Drinking in the Dark in C57BL/6J Mice.
    Brunori G; Weger M; Schoch J; Targowska-Duda K; Barnes M; Borruto AM; Rorick-Kehn LM; Zaveri NT; Pintar JE; Ciccocioppo R; Toll L; Cippitelli A
    Alcohol Clin Exp Res; 2019 Oct; 43(10):2167-2178. PubMed ID: 31386211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Nphe1,Arg14,Lys15]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor.
    Calo G; Rizzi A; Rizzi D; Bigoni R; Guerrini R; Marzola G; Marti M; McDonald J; Morari M; Lambert DG; Salvadori S; Regoli D
    Br J Pharmacol; 2002 May; 136(2):303-11. PubMed ID: 12010780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nociceptin/orphanin FQ receptor antagonists as innovative antidepressant drugs.
    Gavioli EC; Calo' G
    Pharmacol Ther; 2013 Oct; 140(1):10-25. PubMed ID: 23711793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.